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SUMMARY
The use of type I interferons (IFNs) in cancer therapy has been limited by ineffective dosing and significant
toxicity. Here, we exploited the tumor-homing ability of proangiogenic Tie2-expressing monocytes (TEMs)
to deliver IFN-a to tumors. By transplanting hematopoietic progenitors transduced with a Tie2 promoter/
enhancer-driven Ifna1 gene, we turned TEMs into IFN-a cell vehicles that efficiently targeted the IFN response
to orthotopic human gliomas and spontaneous mouse mammary carcinomas and obtained significant anti-
tumor responses and near complete abrogation of metastasis. TEM-mediated IFN-a delivery inhibited tumor
angiogenesis and activated innate and adaptive immune cells but did not impair myelopoiesis and wound
healing detectably. These results illustrate the therapeutic potential of gene- and cell-based IFN-a delivery
and should allow the development of IFN treatments that more effectively treat cancer.INTRODUCTION
Type I interferons (IFN-a and -b) are highly pleiotropic cyto-
kines—produced by virtually every vertebrate cell—that play im-
portant functions in protecting the host from viral infections (Par-
mar and Platanias, 2003; Stark et al., 1998; Stetson and
Medzhitov, 2006). As early as 1969, it was shown that these cy-
tokines also have antitumor activity. Indeed, mice inoculated
with syngeneic tumor cells exhibited significantly increased sur-
vival when treated with type I IFN preparations (Gresser et al.,
1969). This seminal study triggered a wealth of research eventu-
ally leading to clinical testing of type I IFNs in cancer therapy (Be-
lardelli et al., 2002; Brassard et al., 2002).
IFN-awas the first cytokine to show clinical benefit in the treat-
ment of certain types of cancer, including melanoma, chronic
myelogenous leukemia, and renal cancer. High doses of IFN-a
are required to obtain therapeutic responses in cancer patients;
however, these regimens are highly toxic, and the clinical use of
IFN-a has been progressively phased out as alternative pharma-
cological treatments have became available (Belardelli et al.,
SIGNIFICANCE
IFN-a was the first cytokine approved for cancer treatment. However, given the limited efficacy and significant toxicity as-
sociated with systemic IFN-a administration, delivery strategies that improve IFN-a therapeutic index are required. Here,
IFN-a delivery by gene-modified Tie2-expressing monocytes (TEMs) achieved substantial antitumor activity in both preven-
tion and intervention trials but did not cause measurable toxicity. Conversely, expression of IFN-a broadly in hematopoietic
cells or in plasma was highly toxic and, paradoxically, poorly effective. Because stromal cells are the crucial targets of
IFN-a in tumors, resistance to this therapy is unlikely to develop. Hematopoietic progenitors engineered to express
IFN-a specifically in TEM progeny might be administered together with unmodified cells in the setting of autologous
bone marrow transplantation in cancer patients receiving high-dose chemotherapy.
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nias, 2003). Concerning the mechanisms of antitumor activity,
type I IFNs were long thought to act mainly by suppressing tumor
cell proliferation and angiogenesis (Pfeffer, 1997; Sidky and Bor-
den, 1987). These cytokines can directly promote apoptosis of
tumor and stromal cells and may inhibit angiogenesis by down-
regulating the expression of proangiogenic factors in tumors.
More recently, it has been established that IFN-a and -b also
have important roles in regulating the innate and adaptive arms
of the immune system. Indeed, type I IFNs activate dendritic cells
(DCs); upregulate the expression of major histocompatibility
complex (MHC) class I molecules; promote the priming and sur-
vival of T cells; enhance humoral immunity; and increase the cy-
totoxic activity of natural killer (NK) cells, macrophages, and
CD8+ T cells. Moreover, they increase the susceptibility of target
cells (both tumor and stromal cells) to the cytotoxic activities of
immune effectors. Through these immunomodulatory functions,
type I IFNs increase tumor immunogenicity, recruit and activate
immune cells within the tumor milieu, and may eventually facili-
tate tumor rejection (Belardelli et al., 2002; Blankenstein, 2005;
Brassard et al., 2002; Dunn et al., 2006; Theofilopoulos et al.,
2005; Willimsky and Blankenstein, 2007). Recent studies have
further shown that IFN responsiveness in the host hematopoietic
compartment is necessary and sufficient to evoke antitumor ac-
tivity, suggesting that the crucial targets of IFN responses are the
host cells rather than the tumor cells (Dunn et al., 2006). Thus, by
exerting antiproliferative, angiostatic, and immune cell-activating
functions, type I IFNs likely play a vital role in tumor growth con-
trol. Nevertheless, the overall limited therapeutic efficacy of cur-
rent treatments based on type I IFNs might reflect our inability to
target these potent antitumor molecules to the right place and/or
at the right dose. Alternative delivery strategies are thus needed
to achieve safe and effective IFN delivery in cancer patients.
High-dose chemotherapy followed by adjuvant autologous
hematopoietic stem/progenitor cell (HSPC) transplantation has
been tested for the treatment of hematological and solid tumors
and can be regarded as a clinical option for certain types of can-
cer (Fuchs and Whartenby, 2004; Ljungman et al., 2006). As viral
gene transfer strategies become better suited to the clinic, ap-
proaches based on transplantation of genetically modified
HSPCs have the potential to increase significantly the therapeu-
tic efficacy of standard cancer therapies. We and others have re-
cently highlighted the important contribution of bone marrow
(BM)-derived myeloid cells to tumor angiogenesis (de Visser
et al., 2006; Condeelis and Pollard, 2006; De Palma et al.,
2007; De Palma and Naldini, 2006; Shojaei et al., 2008). We iden-
tified, in both mice and humans, a subset of circulating and tu-
mor-infiltrating monocytes that express the angiopoietin recep-
tor Tie2 (Jones et al., 2001) and are proangiogenic. These
Tie2-expressing monocytes (TEMs) are effectively recruited to
tumors, where they play an important role in neoangiogenesis,
but are infrequently found in normal organs (De Palma et al.,
2003, 2005b, 2007; Venneri et al., 2007; Ahn and Brown, 2008;
Du et al., 2008). Based on this unique tumor-homing specificity
among myeloid-lineage cells and the selective expression of
the Tie2 gene in TEMs among the progeny of BM-derived
HSPCs, we explored the possibility of targeting IFN-a to tumors
by expressing it in TEMs from a lentiviral vector (LV) regulated by
Tie2 promoter/enhancer elements (De Palma et al., 2003). By this
300 Cancer Cell 14, 299–311, October 7, 2008 ª2008 Elsevier Inc.strategy, we turned proangiogenic monocytes into tumor-selec-
tive IFN-a delivery vehicles and achieved significant antitumor
activity in orthotopic, spontaneous, and metastatic models of
oncogenesis.
RESULTS
Generation of Mice with TEM-Specific Expression
of an Ifna1 Transgene and Inhibition of Orthotopic
Human Gliomas
We constructed LVs expressing a mouse Ifna1 cDNA either from
promoter/enhancer sequences of the Tie2 gene (Tie2-IFN LV) or
from the ubiquitously active phosphoglycerate kinase (PGK) pro-
moter (PGK-IFN LV). We then transduced HSPCs obtained from
the BM of CD1 athymic (nu/nu) mice with either type of LV and
transplanted the transduced cells into lethally irradiated mice
to obtain mice with TEM-specific (Tie2-IFN mice) or panhe-
matopoietic (PGK-IFN mice) IFN-a expression, respectively. As
controls, we transplanted mice with HSPCs transduced with
Tie2-GFP or PGK-GFP control LVs to obtain Tie2-GFP and
PGK-GFP mice, respectively. A schematic of the experimental
design is shown in Figure 1A.
In liquid culture, HSPCs transduced with the Tie2-IFN LV ex-
pressed IFN-a to a much lower extent than PGK-IFN LV-trans-
duced cells (Figure 1B). This was consistent with the frequency
and mean fluorescence intensity (MFI) of GFP+ cells among
HSPCs transduced with the control Tie2-GFP and PGK-GFP
LVs (Figure 1C). HSPCs transduced with the PGK-IFN LV did
not engraft in lethally irradiated mice, which died 10–12 days af-
ter the transplant with overt BM aplasia (Figure 1D). In contrast,
Tie2-IFN mice were reconstituted long-term by gene-modified
cells (average vector copy number per cell 0.6 ± 0.2) and recov-
ered normal blood cell and platelet counts, hemoglobin, and he-
matocrit (Figure 1E), and all survived until the end of the experi-
ments. Despite the long-term engraftment of gene-modified
cells, IFN-a was not detectable in the plasma of Tie2-IFN mice
by ELISA (data not shown). This latter finding is consistent with
the minimal expression of Tie2 promoter/enhancer-driven trans-
genes in the hematopoietic system. Indeed, in Tie2-GFP mice,
GFP+ cells were only 3%–6% of the total BM cells (Figure 1F)
and 1%–2% of the total leukocytes in the blood, identified as
monocytes by the expression of CD11b and their physical pa-
rameters (Figure 1G). Together, these results show that the
Ifna1 transgene, when expressed from Tie2 transcription ele-
ments in the hematopoietic system, does not interfere with
HSPC engraftment and does not yield systemic IFN-a expression
from the reconstituted transgenic hematopoietic cells.
We inoculated U87 human glioma cells intracranially in Tie2-
IFN (n = 10) and control Tie2-GFP (n = 5) and PGK-GFP (n = 7)
athymic mice 8 weeks after the transplant of the gene-modified
HSPCs and monitored tumor growth by magnetic resonance im-
aging (MRI) for up to 5 weeks post tumor injection (PTI) (Figure 2).
Three weeks PTI, tumor volume reached 24.6 ± 4.3 mm3 in con-
trol mice (including Tie2-GFP and PGK-GFP mice), whereas it
was only 3.8 ± 2.1 mm3 in Tie2-IFN mice (Figure 2A). Of note,
the majority of Tie2-IFN mice were either tumor-free or had tu-
mors barely detectable by MRI at 4 or 5 weeks PTI, whereas all
control mice carried large tumors and had to be euthanized by
this time (Figures 2A–2C and data not shown). Despite their small
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with TEM-Specific Expression of an Ifna1
Transgene
(A) Schematic of the experimental design.
(B) IFN-aexpression by bone marrow (BM)-derived
hematopoietic stem/progenitor cells (HSPCs),
transduced with control (Ctrl) Tie2-GFP, Tie2-IFN,
and PGK-IFN lentiviral vectors (LVs) and expanded
in vitro for 9 days. One experiment representative
of three independent experiments is shown.
(C) GFP expression in transduced HSPCs after
5 days of culture. The percentage and the mean
fluorescence intensity (MFI) of the GFP+ cells are
indicated. One experiment representative of six in-
dependent experiments is shown.
(D) Top: survival curves of HSPC-transplanted
mice. Control mice (Ctrl) include both Tie2-GFP
and PGK-GFP mice. Bottom: hematoxylin and eo-
sin (H&E) staining of whole BM (femur) of represen-
tative control (Tie2-GFP; n = 2) and PGK-IFN (n = 3)
mice analyzed at day 12 posttransplant.
(E) Blood cell counts and hematological parame-
ters (mean ± SEM) in HSPC-transplanted control
(Ctrl; n = 6) and Tie2-IFN (IFN; n = 8) mice. WBC,
white blood cells (3103/ml); RBC, red blood cells
(3106/ml); PLT, platelets; HCT, hematocrit; HGB,
hemoglobin.
(F) FACS analysis of BM cells from representative
Tie2-IFN and Tie2-GFP mice, performed 13 weeks
after HSPC transplantation. The percentage of
GFP+CD11b+ myeloid cells is indicated. One ex-
periment representative of several independent
experiments is shown.
(G) FACS analysis of peripheral blood from a repre-
sentative Tie2-GFP mouse. The GFP+ cells are vir-
tually all CD11b+ (red gate in left panel) and have
light scattering features of monocytes (right panel).
One experiment representative of several indepen-
dent experiments is shown.Cancer Cell 14, 299–311, October 7, 2008 ª2008 Elsevier Inc. 301size, tumors detectable in Tie2-IFN mice appeared more necrotic
than those of control mice as measured by MRI at 3 weeks PTI
(Figure 2D). The Tie2-IFN tumors that grew sufficiently to be ana-
lyzed displayed decreased cell proliferation and greater apopto-
sis (assessed by Ki-67 and cleaved caspase-3 immunostaining,
respectively) as compared to the control tumors (Figure 2E).
In agreement with our previous findings (De Palma et al.,
2007), GFP+ TEMs surrounded angiogenic blood vessels in con-
trol Tie2-GFP tumors (Figure 3A). TEMs were CD11b+ but could
be distinguished from tumor-associated macrophages
(CD11b+GFP) by their small, rounded shape and their preferen-
tial position around blood vessels. Anti-IFN-a antibodies de-
tected several mononuclear cells strongly positive for IFN-a
(IFN-abright) in the gliomas of Tie2-IFN mice, but not of control
mice (Figure 3A and data not shown). The frequency and distri-
bution of IFN-abright cells in Tie2-IFN tumors were similar to those
of GFP+ TEMs in control tumors, suggesting that the IFN-abright
cells represent bona fide IFN-producing TEMs.
Tie2-IFN tumors, but not control tumors, were heavily sur-
rounded and infiltrated by cells expressing Iba1 (Figure 3B),a monocyte/macrophage/microglia protein upregulated upon
cell activation and involved in cell migration and phagocytosis
(Deininger et al., 2002). We previously showed that in these
experimental conditions, the wide majority of glioma-infiltrating
hematopoietic cells are of BM origin and express F4/80, thus
representing tumor-associated macrophages (De Palma et al.,
2005b). Together, these results suggest that the Iba1-expressing
cells in Tie2-IFN tumors represent macrophages activated by
IFN signaling. We then analyzed the expression of a panel of
IFN-a-inducible genes (Honda et al., 2005; Stark et al., 1998) in
the tumors. RNase protection assays (RPA) performed using
a set of mouse-specific probes showed that IFN-responsive
genes were strongly upregulated in the gliomas of Tie2-IFN
mice as compared to control tumors or brain tissue obtained
from the contralateral, noninjected brain hemisphere (Figure 3C).
In particular, 2050-oligoadenylate synthetase (Oas1a, a prototypi-
cal IFN-inducible gene), tumor necrosis factor-a (Tnfa), and
interleukin-1a and -1b (Il1a/b), all typical indicators of type I
IFN-induced responses, were significantly upregulated in Tie2-
IFN tumors. These findings indicated expression of biologically
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IFNs display species specificity of action (Balkwill and Proietti,
1986; Sidky and Borden, 1987). Accordingly, we found that mu-
rine IFN-a inhibited the proliferation of murine cell lines but not
human glioma cells in vitro (see Figure S1 available online).
When we performed RPA using human-specific probes, we did
not detect significant expression of IFN-inducible genes in
Tie2-IFN gliomas, indicating that the IFN pathway was minimally
activated in the tumor cells of human origin (Figure 3C). These re-
sults indicate that an IFN response targeted to the host-derived
components of the tumor is capable of inhibiting human glioma
growth in the mouse brain.
We then studied tumor angiogenesis. There were striking dif-
ferences in the vascularization of control and Tie2-IFN gliomas
(Figure 4A). Whereas the blood vessels of control tumors were
notably enlarged and tortuous, those of Tie2-IFN tumors were
small, had a regular profile, and were richly covered by NG2+ peri-
cytes, all typical features of quiescent or ‘‘normalized’’ blood ves-
sels. The relative vascular area of Tie2-IFN tumors was only 33%
of that of control tumors, and the blood vessels of Tie2-IFN tu-
mors contained fewer Ki-67+ proliferating endothelial cells
(ECs) and increased numbers of caspase-3+ apoptotic cells com-
pared to those of control tumors (Figure 4B). Together, these find-
Figure 2. Inhibition of Orthotopic Human Gliomas in
Tie2-IFN Athymic Mice
(A) Glioma growth (mean tumor volume ± SEM, measured by
MRI) in individual control (Ctrl; n = 11 of 12) and Tie2-IFN
(IFN; n = 9 of 10) mice at 3 weeks post tumor injection (PTI).
Ctrl mice include both Tie2-GFP (n = 5) and PGK-GFP (n = 6)
mice.
(B) Glioma growth in individual mice from week 1 to week 5
PTI. Note that 4 Tie2-IFN and 5 control mice were euthanized
at 4 weeks PTI for further analyses.
(C) Contrast-enhanced T1-weighted (week 1, 2, and 5) and T2-
weighted (week 3) coronal MRI images showing brain tumor
growth at the indicated time points PTI in representative con-
trol PGK-GFP (Ctrl) and Tie2-IFN (IFN) mice. Intracranial glio-
mas are indicated by arrows and dashed line.
(D) Tumor necrotic fraction (mean necrotic fraction, % ± SEM)
by MRI in individual control (Ctrl; n = 7) and Tie2-IFN (IFN; n = 5)
mice at 3 weeks PTI.
(E) Ki-67 or caspase-3 (Casp-3; green) and CD31 (red) immu-
nostaining and TO-PRO-3 (TP3) nuclear staining (blue) of intra-
cranial gliomas grown in control Tie2-GFP (Ctrl) and Tie2-IFN
(IFN) mice. Arrows show Ki-67+CD31+ or caspase-3+CD31+
endothelial cells (ECs); dashed line indicates tumor margin.
Brain sections were analyzed at 4 or 5 weeks PTI. Histograms
at right show quantification (mean frequency of marker-posi-
tive cells, % ± SD; n = 3–5) of Ki-67+ or caspase-3+ cells.
ings strongly suggest that blood vessels of Tie2-IFN
gliomas are in a quiescent, nonangiogenic state.
Tumor Growth and Myelotoxicity
in Mice Expressing Systemic IFN-a
In order to better assess the advantages of tar-
geted delivery, we studied the safety and efficacy
of IFN-a in a model of systemic administration. To
obtain mice with systemic IFN-a expression
(s-IFN mice), we intravenously injected a group of
Tie2-GFP mice with PGK-IFN LVs. By intravenous injection,
LVs preferentially transduce the liver and the spleen, where
they establish a stable source of the transgene product (Brown
et al., 2006). Three weeks following LV injection, s-IFN mice ex-
pressed easily detectable IFN-a in the plasma (418 ± 124 pg/ml;
mean ± SD; n = 4) as measured by ELISA. In this model of
systemic expression, IFN-a failed to inhibit glioma growth and in-
duced myelotoxicity with marked thrombocytopenia (Figure S2).
Moreover, systemic IFN-a induced progressive body weight loss
in s-IFN mice (data not shown). In agreement with these obser-
vations, elevated doses of IFN-a have suppressive effects on
hematopoiesis and are toxic in humans (Belardelli et al., 2002;
Parmar and Platanias, 2003). Together with the data of Figures
1–4 above, these results show that tumor-targeted IFN-adelivery
by TEMs, but not its ubiquitous expression in BM-derived cells or
sustained expression in the plasma, achieves substantial antitu-
mor activity in an orthotopic human glioma model without induc-
ing systemic toxicity.
Preferential Activation of the Tie2 Promoter/Enhancer
in the Tumor Microenvironment
It may appear difficult to reconcile the lack of myelotoxicity
with the strong antitumor effects observed in Tie2-IFN mice.
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quantitative PCR (qPCR) in TEMs isolated to near homoge-
neity from FVB/Tie2-GFP transgenic mice (De Palma et al.,
2005b) carrying subcutaneous N202 breast carcinomas. We
found that Tie2 mRNA was expressed more in tumor-derived
than in blood-derived TEMs (Figure 4C). Similarly, when we
measured the expression of the Tie2 promoter/enhancer-
driven GFP transgene, we found that the GFP MFI was
higher (3-fold) in tumor- versus blood-derived TEMs (Fig-
ure 4C). These findings suggest that promoter-dependent
upregulation of transgene expression at the tumor site, to-
gether with the preferential homing of TEMs to angiogenic
blood vessels, contributes to effectively targeting IFN-a to
tumors.
Figure 3. Tumor-Targeted IFN Response in Tie2-IFN Athymic Mice
(A and B) GFP or Iba1 immunostaining (green), CD31 or IFN-a immunostaining
(red), and CD11b immunostaining or TP3 nuclear staining (blue) of intracranial
gliomas grown in control Tie2-GFP (Ctrl) and Tie2-IFN (IFN) mice. Inset in (A)
shows high-power magnification of an IFN-a-expressing cell. Brain sections
were analyzed at 4 or 5 weeks PTI. Photos are representative of results ob-
tained from 3–6 mice per group.
(C) RNase protection assay performed at 4 weeks PTI using mouse (left panel)
or human (right panel) gene probes. T, tumor; P, brain parenchyma from con-
tralateral hemisphere. The housekeeping gene RPL32 was used to estimate
the amount of mouse and human mRNA in each sample. The rightmost lane
in each panel represents positive control. Results are representative of 4
Tie2-IFN (IFN) and 4 PGK-GFP (Ctrl) mice analyzed at 4 (n = 2) or 5 (n = 2) weeks
PTI.
Inhibition of Established Mammary Tumors
in MMTV-PyMT Transgenic Mice
We then assayed the antitumor activity of IFN-a in a spontaneous
model of mammary carcinogenesis. In the MMTV-PyMT mouse
model (FVB strain), multiple breast tumors caused by expression
of the polyoma middle T (PyMT) oncoprotein in the mammary ep-
ithelium progress through well-characterized stages, and 90% of
the tumor-bearing mice develop lung metastases by 12–14
weeks of age (Husemann et al., 2008; Lin et al., 2001, 2003).
We studied the recruitment of TEMs to MMTV-PyMT tumors.
We transplanted HSPCs obtained from Tie2-GFP transgenic
mice (De Palma et al., 2005b) into 5.5-week-old female MMTV-
PyMT mice (Figure 5A), which are known to carry mammary
lesions developed to the hyperplastic/dysplastic stage (Huse-
mann et al., 2008; Lin et al., 2001, 2003). We then analyzed the
tumors 1.5, 4, and 6 weeks later (i.e., at 7, 9.5, and 11.5 weeks
of age, respectively). Examination of the mammary glands of
the transplanted mice revealed the presence of multiple
Figure 4. Inhibition of Glioma Angiogenesis in Tie2-IFN Mice and
Preferential Activation of the Tie2 Promoter/Enhancer in the Tumor
Microenvironment
(A) NG2 (green), CD31 (red), and CD11b (blue) immunostaining of intracranial
gliomas grown in control Tie2-GFP (Ctrl) and Tie2-IFN (IFN) mice. The right-
most panel shows high-power magnification of a tumor vessel covered by
NG2+ pericytes. Brain sections were analyzed at 4 or 5 weeks PTI. Photos
are representative of results obtained from 3–6 mice per group.
(B) Vascular area (mean fold increase over reference value [Ctrl] ± SD) and
quantification of Ki-67+CD31+ or caspase-3+CD31+ ECs (mean frequency of
marker-positive cells, % ± SD) in gliomas of control (Ctrl, includes Tie2-GFP
[n = 5] and PGK-GFP [n = 3]) and Tie2-IFN (IFN; n = 5) mice. Brain sections
were analyzed at 4 or 5 weeks PTI.
(C) Left: qPCR analysis of Tie2 transcript in tumor-derived ECs and Tie2-ex-
pressing monocytes (TEMs) and blood-derived TEMs isolated from FVB/
Tie2-GFP transgenic mice. Results show DCt values (mean ± SEM; n = 2 bio-
logical samples) versus endogenous control Gapdh. The lower the DCt, the
higher the expression of the transcript. Tumor-derived ECs are used as a refer-
ence Tie2+ cell type. Right: GFP MFI (in mean arbitrary units [a.u.] ± SEM;
n = 5–6) of blood- and tumor-derived TEMs from Tie2-GFP transgenic mice.
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(A) Schematic of the early-intervention trial.
(B) Representative sections of breast tumors (n = 2 mice per group; 5–12 tumors per mouse) analyzed 1.5, 4, and 6 weeks after transplantation of Tie2-GFP-trans-
genic HSPCs into 5.5-week-old MMTV-PyMT mice. Top row of images: H&E staining. Bottom row of images: GFP (green) and CD31 (red) immunostaining and
TP3 nuclear staining (blue).
(C) Schematic of the late-intervention trial.
(D) Tumor growth in representative mice treated according to an early-intervention schedule. Axial noncontiguous serial T2-weighted MRI images (a–e and f–j)
show primary tumors at the three anterior mammary glands (1, 2, and 3) of representative control (Ctrl; a–e) and Tie2-IFN (IFN; f–j) MMTV-PyMT mice at 14 weeks
of age.
(E) Mammary tumor growth (mean volume ± SEM by MRI analysis of the three anterior mammary glands) at 12 and 14 weeks of age in control (Ctrl; n = 8) and Tie2-
IFN (IFN; n = 9) MMTV-PyMT mice treated according to an early-intervention schedule (two experiments combined).
(F) Mammary tumor growth (mean volume ± SEM) at 12 and 14 weeks of age in control (Ctrl; n = 15) and Tie2-IFN (IFN; n = 14) MMTV-PyMT mice treated accord-
ing to a late-intervention schedule (two experiments combined).
(G) Irf7 (top) andOas1a (bottom) expression as measured by qPCR (mean fold increase over reference value [control brain] ± SEM) in tumors and organs of control
(Ctrl; n = 4 for organs; n = 8 for tumors) and Tie2-IFN (IFN; n = 4 for organs; n = 9 for tumors) MMTV-PyMT mice. Samples were analyzed at 14.5 weeks of age. Only
p values < 0.05 are indicated.
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and locally invasive carcinomas were observed at 9.5 and 11.5
weeks (Figure 5B). We detected GFP+ TEMs in the tumors at 4
and 6 weeks (carcinoma stage), but not at 1.5 weeks (hyperpla-
sia/adenoma stage) posttransplant (Figure 5B). These findings
suggest that TEM-mediated gene delivery at the tumor site is de-
layed a few weeks following HSPC transplantation. This is con-
sistent with both the expected kinetics of hematopoietic recon-
stitution from the transplanted HSPCs and the enhanced
recruitment of BM-derived myeloid cells that occurs concomi-
tantly with malignant transition (de Visser et al., 2006; Lin et al.,
2001).
We then transplanted Tie2-IFN LV-transduced or mock-
transduced HSPCs into either 5.5- or 8.5-week-old female
MMTV-PyMT mice. Because of the delayed TEM recruitment
to the tumors, both gene delivery schedules target established
carcinomas and can be regarded as ‘‘early’’ and ‘‘late’’ inter-
vention trials, respectively (Figures 5A and 5C). We observed
a clear delay in the onset and development of mammary tumors
in Tie2-IFN- (IFN) versus mock-transduced (Ctrl) mice in two in-
dependent early-intervention trials as assessed by biweekly in-
spections of the mammary glands (data not shown). Further
analyses performed by MRI showed that tumor growth was
significantly inhibited in Tie2-IFN mice (Figures 5D and 5E): at
12 weeks of age, tumor volume in Tie2-IFN mice (n = 9) was
56% of that of control mice (n = 8), and this difference in-
creased at 14 weeks of age, when tumor volume in Tie2-IFN
mice was only 42% of that of the controls. When we trans-
planted MMTV-PyMT mice according to a late-intervention
schedule (8.5 weeks of age), tumors were already palpable in
the majority of mammary glands. We obtained significant
inhibition of tumor growth in two independent experiments
(Figure 5F): at 12 weeks of age, the tumor volume in Tie2-IFN
mice (n = 14) was 62% of that of control mice (n = 15), and
this difference increased at 14 weeks of age, when the tumor
volume in Tie2-IFN mice was only 49% of that of control
mice. Together, these data show significant antitumor re-
sponses both in early- and late-intervention trials and demon-
strate the increasing therapeutic activity at 14 versus 12 weeks.
It is noteworthy that these IFN responses were achieved in spite
of the relatively low vector copy number per cell in the BM of
the transplanted mice examined at the end of the experiments
(Tie2-IFN 0.35 ± 0.09; n = 13). In these experiments, MRI data
were confirmed by postmortem tumor weight measurements
performed at 14.5 weeks (data not shown), when all of the
mice were euthanized because of the large tumor burden in
control mice.
We then investigated the antitumor responses in Tie2-IFN
mice. To prove that tumor inhibition was associated with in situ
activation of a type I IFN response, we measured the expression
of the interferon-inducible genes interferon regulatory factor-7
(Irf7) and Oas1a at 14.5 weeks of age (Honda et al., 2005; Stark
et al., 1998) by qPCR in tumors and organs of the transplanted
mice. Both genes were significantly upregulated in tumors of
Tie2-IFN mice as compared to those in controls (Figure 5G). By
contrast, we found no increase of Irf7 and Oas1a in the organs
of Tie2-IFN mice. This was also true for BM, spleen, and liver,
which contain substantial hematopoietic populations derived
from the transplanted HSPCs. These data provide molecularevidence for the selective targeting of the IFN response to the tu-
mors of Tie2-IFN MMTV-PyMT mice.
Tumor-infiltrating hematopoietic cells are important effectors
of tumor rejection processes (Willimsky and Blankenstein,
2007). Whereas the frequency of infiltrating CD45+ hematopoi-
etic cells and CD68+ macrophages was similar in Tie2-IFN and
control tumors, there was a dramatic increase in the fraction of
innate immune cells expressing DC (CD11c) and cell activation
markers (Iba1) specifically in Tie2-IFN tumors (Figure 6A and
data not shown). Of note, a substantial proportion of the
CD11c+ DCs and CD68+ macrophages coexpressed Iba1 in
Tie2-IFN tumors, a feature consistent with IFN-mediated activa-
tion (Tosi et al., 2004). NK cells, identified by expression of the
alpha 2 integrin (CD49b/DX5), were observed at low frequency
in both Tie2-IFN and control tumors and were mostly found clus-
tered in discrete tumor areas (Figure S3). When isolated from the
spleen of tumor-bearing mice, NK cells of Tie2-IFN mice had su-
perior cytolytic activity as compared to cells from control mice
(Figure 6B). Regarding adaptive immune cells, we found greatly
increased infiltration of both CD4+ and CD8+ T lymphocytes in
Tie2-IFN tumors as compared to controls (Figure 6C). These
findings were confirmed by fluorescence-activated cell sorting
(FACS) analysis of tumor-derived single-cell suspensions
(Figure 6D). Importantly, the frequency of effector T cells (Open-
shaw et al., 1995) was higher in Tie2-IFN tumors than in control
tumors as revealed by expression of CD44 in CD4+ and CD8+
T cells and their ability to express IFN-g upon restimulation
ex vivo. Together, these findings suggest that TEM-mediated
IFN-a delivery enhances the recruitment and promotes the
activation of both innate and adaptive immune cells.
We noted that tumor growth in MMTV-PyMT mice was associ-
ated with a progressive increase in blood leukocyte counts and
a measurable decrease in erythrocyte counts and hemoglobin
level (Figure 7A). IFN-a delivery by TEMs attenuated such tu-
mor-driven hematological abnormalities (Figure 7B); importantly,
these effects could not be interpreted as IFN-induced toxicity
because the number of circulating platelets and the frequency
of BM-derived colony-forming cells (CFCs) were similar in
Tie2-IFN, control (transplanted), and wild-type (nontransplanted)
mice (Figures 7B and 7C). In transplanted tumor-bearing mice,
the majority of the circulating leukocytes were CD11b+ or
CD11b+Gr1+ myeloid cells (Figure S4), which have been shown
to be protumoral and proangiogenic (Shojaei et al., 2008). Of
note, the CD11b+ myeloid cell counts were significantly reduced
in the IFN-treated mice (Figure S4).
We observed TEMs at the expected frequency in both blood
and tumors of Tie2-IFN and control mice (Figure 7D; Figure S4),
indicating that the expression of the Ifn1a transgene does not
affect TEM mobilization from the BM, nor does it impair their
homing to tumors.
Suppression of Metastasis in MMTV-PyMT
Transgenic Mice
We then analyzed the lungs of MMTV-PyMT mice treated
according to an early-intervention schedule to detect antitumor
responses at the metastatic site. We analyzed the lungs of trans-
planted mice by serial sectioning the entire left lung and scoring
for the presence of metastatic nodules (Figures 8A and 8B). All
control mice had metastatic outgrowth in the lung, with 7 of 8
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IFN MMTV-PyMT Mice
(A) CD45 or Iba1 (green) and CD11c or CD68 (red)
immunostaining and TP3 nuclear staining (blue) of
MMTV-PyMT mammary tumors grown in control
(Ctrl) and Tie2-IFN (IFN) mice. Tumors were ana-
lyzed at 14.5 weeks of age. Histograms at right
show quantification of CD45+, Iba1+, and
CD11c+ areas (mean fold increase over reference
value [Ctrl] ± SEM; n = 3 mice per group; n = 12 tu-
mors per mouse).
(B) NK chromium release assays. Cytolytic activity
at different effector (NK cells)/target (YAC-1 cells)
ratios of NK cells obtained from the spleen of con-
trol (Ctrl) and Tie2-IFN (IFN) tumor-bearing mice
(percentage of maximal chromium release ± SEM;
n = 3–5 technical replicates) is shown. Two inde-
pendent experiments are shown. p % 0.01 at all
effector/target ratios.
(C) CD4 or CD8 immunostaining (red) and TP3 nu-
clear staining (blue) of MMTV-PyMT mammary tu-
mors grown in control (Ctrl) and Tie2-IFN (IFN)
mice. Tumors were analyzed at 14.5 weeks of
age. Histograms at right show quantification of
CD4+ and CD8+ cells (mean frequency of marker-
positive cells, % ± SEM; n = 3 mice per group;
n = 4 tumors per mouse).
(D) FACS analysis of tumor-derived cells (mean fre-
quency of marker-positive cells, % ± SEM; n = 7
mice per group; n = 5 tumors per mouse). Upper
histograms: frequency of CD8+ or CD4+ cells after
physical gating on viable tumor-derived cells. Mid-
dle histograms: frequency of CD44+IFN-g+ cells
within CD8+ or CD4+ cells. Lower histograms: fre-
quency of CD8+CD44+IFN-g+ or CD4+CD44+
IFN-g+ effector T cells within viable tumor-derived
cells. Before analysis of IFN-g expression, cells
were stimulated ex vivo by phorbol myristate ace-
tate (PMA) and ionomycin.mice showing metastatic foci in virtually all examined lung sec-
tions, indicating that multiple and large metastases had devel-
oped in these mice (0.4–25.2 metastatic foci per section per
mouse, average 9.2; n = 8 mice; 16–24 sections examined per
mouse). By contrast, Tie2-IFN mice were either free from detect-
able nodules (n = 3) or had few small foci per lung (0–0.8 meta-
static foci per section per mouse, average 0.2; n = 9 mice; 16–
24 sections examined per mouse; p < 0.001 for control versus
Tie2-IFN by Mann-Whitney test). When we calculated the total
tumor area in the examined lung sections of each mouse, it
was 300-fold higher in control versus Tie2-IFN mice (p < 0.001
by Mann-Whitney test). These results indicate that our therapeu-
tic strategy can effectively suppress metastasis in MMTV-PyMT
mice.
Wound Healing in Tie2-IFN Mice
Our studies demonstrated that TEM-mediated IFN-a delivery
achieved substantial antitumor activity without causing detect-
able hematopoietic toxicity. We then investigated whether this
strategy would impair tissue repair. To address this question,
we performed a wound healing assay in FVB/Tie2-IFN and con-
trol mice 8 weeks after HSPC transplantation. We found no evi-
dence of impaired wound healing in Tie2-IFN mice as assessed
306 Cancer Cell 14, 299–311, October 7, 2008 ª2008 Elsevier Inc.by monitoring the healing response (Figure 8C) and by histolog-
ical examination of the skin at 10 days post injury (Figure 8D). As
shown in Figure 8D, keratinocyte proliferation and angiogenesis
were induced similarly below the wound in both control and Tie2-
IFN mice.
DISCUSSION
Monocyte-Mediated Targeting of IFN-a to Tumors
Here, we describe a gene delivery strategy to target IFN-a to
tumors. By exploiting LV gene transfer into HSPCs and making
transgene expression responsive to the signals that activate
Tie2 in tumor-infiltrating hematopoietic cells, we turned proan-
giogenic monocytes into efficient cellular vehicles for the tar-
geted delivery of IFN-a to tumors. In orthotopic human gliomas
and transgenic mice spontaneously developing metastatic
breast cancer, IFN-a-expressing TEMs triggered antitumor
responses in the absence of systemic IFN-a expression, and
without inducing detectable toxicity. In these mice, antitumor
responses recapitulated the well-known activities of type I
IFNs: inhibition of angiogenesis, recruitment and activation
of innate and adaptive immune cells, and induction of cell
apoptosis.
Cancer Cell
Tumor-Targeted IFN-a Delivery by Tie2+ MonocytesIFN-a has been used for the treatment of several types of can-
cer, including hematological malignancies, melanoma, Kaposi’s
sarcoma, and renal carcinoma (Belardelli et al., 2002; Brassard
et al., 2002). However, only a small proportion of patients benefit
from IFN therapy, and significant toxicity is often associated with
the maximal tolerated doses that are required to obtain thera-
peutic responses. Several factors may limit the efficacy of sys-
temic IFN therapy. First, IFN bioavailability at the tumor site
may vary significantly with the tumor type, burden, and adminis-
tration protocol. Intravenous and subcutaneous dosing of re-
combinant type I IFN are associated with a systemic half-life of
a few hours, which may expose the tumor to only short bursts
of therapy (Salmon et al., 1996). In addition, preclinical studies
in mouse models have indicated that antitumor activity of IFNs
displays a bell-shaped dose-response curve (Slaton et al.,
1999; Solorzano et al., 2003). These data suggest that maximal
tolerated doses may induce counterregulatory mechanisms
that disable cytokine activity, whereas optimal biological doses
may be therapeutic (Curnis et al., 2005; Shaked et al., 2005).
Yet it may be difficult to identify optimal biological doses in can-
cer patients, and clinical testing of low-dose IFN-a showed no
impact on survival in melanoma patients (Belardelli et al.,
2002). Thus, delivery strategies that target type I IFNs to the
tumor site without inducing systemic overexpression may be
advantageous.
The bone marrow is a source of nonendothelial, proangiogenic
hematopoietic cells that are recruited to tumors, where they ap-
Figure 7. Lack of Myelotoxicity in Tie2-IFN
MMTV-PyMT Mice
(A) Blood cell counts and hematological parame-
ters (mean values ± SEM) of nontransplanted
FVB (wild-type; n = 3) and MMTV-PyMT (PyMT;
n = 3) mice analyzed at the indicated time points.
Abbreviations as in Figure 1E.
(B) Blood cell counts and hematological parame-
ters (mean values ± SEM) of mice from early (left
panels) and late (right panels) intervention trials.
Data from individual nontransplanted FVB (wild-
type; n = 3–5) and transplanted control (Ctrl; n =
9–13) and Tie2-IFN (IFN; n = 9–13) MMTV-PyMT
mice are shown. Analyses were performed at
14.5 weeks of age.
(C) Colony-forming cell (CFC) assays (mean num-
ber of CFCs/105 BM cells ± SEM) in BM of control
(Ctrl; n = 4–7) and Tie2-IFN (IFN; n = 5–7) MMTV-
PyMT mice, as measured at 14.5 weeks of age.
Two independent experiments (left, early-inter-
vention trial; right, late-intervention trial) are
shown. p > 0.05 for both experiments.
(D) GFP (green) and CD31 (red) immunostaining
and TP3 nuclear staining (blue) of representative
control (Ctrl) and Tie2-IFN (IFN) MMTV-PyMT tu-
mors analyzed at 14.5 weeks of age (n = 4).
pear to provide paracrine support for an-
giogenesis (De Palma et al., 2003; De
Palma and Naldini, 2006; Ahn and Brown,
2008). By using tumor-infiltrating mono-
cytes as a cellular vehicle for the trans-
port of IFN-a to tumors, we speculated
that continuous, low-dose IFN-a would be released at the tumor
site, possibly achieving biologically active concentrations with-
out inducing counterregulatory responses and systemic toxicity.
We observed strong antitumor responses in Tie2-IFN mice in
spite of the fact that IFN-a was not detectable in the plasma by
ELISA and demonstrated in situ activation of type I IFN signaling
in tumors. TEMs effectively and selectively targeted IFN to the tu-
mors, as shown by the upregulation of IFN-inducible genes in the
tumors but not in the other tissues and organs analyzed. The tu-
mor-homing specificity of TEMs, together with the upregulation
of the Tie2 promoter/enhancer-driven transgene in TEMs upon
their homing to the tumor, may well explain the selectivity of
IFN-a expression at the tumor site, the effective antitumor activ-
ity, and the lack of myelotoxicity in Tie2-IFN mice. It is possible
that IFN-a, when released by TEMs in the tumor microenviron-
ment, may induce expression of endogenous IFN genes in neigh-
boring cells through a paracrine loop, in analogy with spreading
antiviral responses triggered by type I IFNs (Stetson and Medz-
hitov, 2006). In this regard, the sensitivity of the immunostaining
procedure used to detect IFN-a-producing TEMs in our studies
may have prevented the detection of a larger fraction of tumor-
associated cells expressing IFN-a at low level.
Mechanisms of Antitumor Activity: Inhibition
of Angiogenesis and Activation of Immune Cells
Concerning the mechanisms of antitumor activity, we noted
a clear antiangiogenic effect in human gliomas inoculated in
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Tumor-Targeted IFN-a Delivery by Tie2+ MonocytesTie2-IFN mice. In these tumors, the relative vascular area was
greatly reduced and the blood vessels had features of co-opted
or ‘‘normalized’’ vasculature, consistent with the reported angio-
static activities of type I IFNs. The preferential localization of
TEMs in the proximity of sprouting blood vessels may contribute
to this antiangiogenic effect, by generating locally effective
IFN-a concentration at the angiogenic site. Type I IFNs can in-
hibit angiogenesis by exerting direct antiproliferative and proa-
poptotic activity on ECs and by downregulating the expression
Figure 8. Inhibition of Metastasis and Normal Wound
Healing in Tie2-IFN MMTV-PyMT Mice
(A) Number of metastatic foci (gray bars) and mean area of sin-
gle metastasis (broken black line) in individual serial sections
(individual bars) obtained from the entire left lung of individual
control (Ctrl; n = 8) and Tie2-IFN (IFN; n = 9) MMTV-PyMT mice
treated according to an early-intervention schedule and ana-
lyzed at 14.5 weeks of age. Numbers indicate the average
number of metastases per section in each individual mouse.
See text for statistical analysis.
(B) H&E staining of representative lung sections of control
(Ctrl; n = 8) and Tie2-IFN (IFN; n = 9) MMTV-PyMT mice ana-
lyzed at 14.5 weeks of age.
(C) Photos of healing of wounds at 10 days post injury in con-
trol (Ctrl; n = 4) and Tie2-IFN (IFN; n = 4) FVB mice.
(D) Left panels: H&E staining of representative (n = 4) skin sec-
tions analyzed at 10 days post injury. ker: keratinocytes. Right
panels: CD31 immunostaining (red) and TP3 nuclear staining
(blue) of adjacent sections. Wide-field images showing CD31
immunostaining were reconstructed by superimposition of
overlapping confocal planes acquired at 1003 magnification.
of proangiogenic factors in tumor cells (Dinney
et al., 1998; Slaton et al., 1999; Solorzano et al.,
2003). We did not observe an antiangiogenic effect
in the mammary tumors of Tie2-IFN mice (data not
shown), suggesting the prevalence of other mecha-
nisms driving the antitumor response in this model.
Activation of tumor-infiltrating immune cells may
represent one such mechanism. Indeed, we ob-
served robust upregulation of Iba1, a macro-
phage-lineage activation marker, in tumor-associ-
ated macrophages and DCs of Tie2-IFN mice. In
the MMTV-PyMT model, we found enhanced tu-
mor infiltration by DCs and effector T cells and ac-
tivation of NK cells. The finding of activated NK
cells in the spleen of Tie2-IFN mice may seem to
contradict the notion that TEM-mediated IFN re-
sponses are specifically targeted to tumors. How-
ever, it has been shown that DCs activated by
type I IFNs migrate to lymphoid organs, where
they are able to transactivate NK cells via the re-
lease of IL-15 (Lucas et al., 2007). We observed
greatly enhanced infiltration of Iba1+CD11c+ DCs
in the tumors of Tie2-IFN MMTV-PyMT mice,
consistent with the ability of IFN-a to promote DC
maturation and activation (Belardelli et al., 2002;
Brassard et al., 2002; Tosi et al., 2004). It can be en-
visioned that IFN-activated DCs may in turn acti-
vate NK cells in the lymphoid organs of Tie2-IFN
mice. Of note, the enhanced recruitment and acti-
vation of DCs in the tumors of IFN-treated mice may also contrib-
ute to promote antitumor immunity by other immune cell types,
such as T cells. Because wound healing was not impaired in
Tie2-IFN mice, it is likely that the induction of immune responses
has a key role in mediating the antitumor activity of IFN-a.
Schreiber and colleagues have shown that host hematopoietic
cells, and not tumor cells, need to express functional type I IFN
receptor (IFNAR)—and thus be sensitive to type I IFNs—for tu-
mor rejection to occur (Dunn et al., 2006). In another study, the
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gated in Stat1-deficient hosts, which are insensitive to IFN-a (Le-
sinski et al., 2003). These data indicate that both endogenous
and exogenous type I IFNs primarily target tumor-infiltrating/
stromal cells. Perhaps our most relevant finding in support of
this notion was obtained in the glioma model. Indeed, in tumors
of these mice, IFN-inducible genes were strongly upregulated in
the host compartment, but not in the tumor cells, which are of hu-
man origin and insensitive to mouse IFN-a. Yet the IFN response
targeted to the host-derived components of the tumor was suf-
ficient to inhibit tumor growth. From a clinical perspective, a ther-
apeutic strategy targeting the tumor stroma may be applied to
a broad range of tumors and may have a lower likelihood to se-
lect resistance. Moreover, therapeutic responses may also be
obtained in the absence of an adaptive immunity against tu-
mor-associated antigens.
Effects on Metastasis
A remarkable result was the near complete control of metastatic
growth obtained in MMTV-PyMT Tie2-IFN mice treated accord-
ing to an early-intervention schedule. Because metastatic dis-
semination occurs early in this breast cancer model (Husemann
et al., 2008), it is unlikely that the reduced primary tumor burden
in Tie2-IFN mice fully accounts for the suppression of metastasis.
Rather, we can envisage that the cytostatic and cytotoxic re-
sponses triggered by IFN at the primary tumor site may have pre-
vented progression to a metastatic stage (Kouros-Mehr et al.,
2008). In the late-intervention trial, we achieved significant con-
trol of the primary tumors but could not reliably assess efficacy
on metastases. Indeed, we found many fewer and smaller metas-
tases, in both control and treated mice, than in early-intervention
trials, possibly as a consequence of the late irradiation schedule
(data not shown). In addition, it is likely that the short follow-up
time available in the late-intervention trial would not allow for de-
tecting a significant response at the metastatic site. Future stud-
ies in other metastatic tumor models that allow for longer follow-
up times will be needed to ascertain the therapeutic potential of
TEM-mediated IFN delivery on established metastases.
Clinical Relevance and Therapeutic Opportunities
Our results indicate that full donor chimerism with gene-modified
cells in transplanted mice is not required to achieve therapeutic
benefit. Indeed, transplanted mice carried an average of 0.4–0.6
Tie2-IFN LV copies per cell at long-term analysis, with some
mice showing as few as 0.1 copies per cell. These data argue
in favor of the feasibility of a future clinical translation of our strat-
egy. Indeed, one could perform minitransplant of gene-modified
autologous HSPCs based on mild conditioning or infuse gene-
modified HSPCs together with unmodified cells, in combination
with or subsequent to standard cancer therapies. On the basis of
available data, high-dose chemotherapy followed by autologous
HSPC transplantation can be regarded as a clinical option not
only for several hematologic malignancies but also for certain
types of solid cancers, including neuroblastoma, Ewing sar-
coma, and germ cell tumors (Ljungman et al., 2006). Our mouse
glioma model may suggest that transplantation of gene-modified
autologous HSPCs could prevent or delay the local recurrence of
glioblastoma in cancer patients following surgical debulking or ir-
radiation of the tumor mass. Our data from MMTV-PyMT micetreated according to a late-intervention schedule further suggest
that antitumor responses might be obtained even in patients with
advanced and metastatic cancer. Although we did not observe
obvious myelotoxicity when we delivered IFN-a by TEMs, Tie2
is expressed by primitive hematopoietic stem cells (Jones
et al., 2001). Thus, further long-term studies, also employing hu-
man hematochimeric mouse models, should be performed to
better assess the potential toxicity of our delivery strategy. If
required, advanced-design LVs may be developed to restrict
IFN-a expression to mature hematopoietic cells (Brown et al.,
2006) or to the desired time window (Vigna et al., 2005), and
the inclusion of a suicide gene in the gene expression cassette
may enable elimination of the gene-modified cells if required
(Bordignon, 2006).
Because of their reported tumor tropism, distinct types of
stem cells—including mesenchymal and neural stem cells—are
currently being tested as gene delivery vehicles for cell-based
cancer therapy (Aboody et al., 2008). However, these cell types
must be exogenously infused in large amounts, and their inher-
ent protumoral or immunosuppressive activities might represent
a threat to successful therapy. Our gene delivery strategy is not
based on additive cell therapy; rather, it exploits an endogenous
cell compartment, which is renewed constantly by long-term re-
populating cells. Moreover, by turning TEMs into IFN-expressing
cells, our strategy antagonizes the protumoral activity of a natu-
rally occurring tumor-infiltrating cell type.
Tumor-associated hematopoietic cells have long been
thought to represent ideal vehicles for the transport of therapy
to tumors (Bordignon, 2006). However, this strategy has been
hampered until now by inefficient gene delivery into long-term re-
populating cells and the lack of a suitable cellular vehicle that
could be used to safely and selectively transfer the therapeutic
factor to tumors. Our studies now provide proof of feasibility of
a gene therapy strategy wherein ex vivo transduction of HSPCs
can be used to safely and effectively deliver IFN-a, and possibly
other cancer biotherapeutics, in a tumor-targeted fashion.
EXPERIMENTAL PROCEDURES
Lentiviral Vectors
The Tie2-GFP and PGK-GFP lentiviral transfer vectors were described previ-
ously (De Palma et al., 2005b). The Tie2-IFN and PGK-IFN lentiviral transfer
vectors were generated by cloning a murine Ifna1 cDNA in place of the GFP
cDNA into the Tie2-GFP and PGK-GFP lentiviral transfer vectors, respectively.
Concentrated VSV-G-pseudotyped LV stocks were produced and titered as
described previously (De Palma and Naldini, 2002).
Mice
FVB and CD1 athymic (nu/nu) mice were purchased from Charles River Labo-
ratories (Calco, Milan). FVB/MMTV-PyMT mice were purchased from the NCI-
Frederick Mouse Repository and established as a colony at the San Raffaele
animal facility. The strain was maintained by breeding hemizygous males
with FVB wild-type females. FVB/Tie2-GFP transgenic mice were generated
by LV-mediated transgenesis as described previously (De Palma et al.,
2005b). All procedures were performed according to protocols approved by
the Animal Care and Use Committee of the Fondazione San Raffaele del Monte
Tabor (IACUC 231, 324, 335) and communicated to the Ministry of Health and
local authorities according to Italian law.
HSPC Transduction and Transplantation
Six-week-old female CD1 athymic, FVB, and FVB/Tie2-GFP mice were
killed with CO2, and BM was harvested by flushing the femurs and tibias.
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purification kit (StemCell Technologies) and transduced with concentrated LVs
as described previously (De Palma and Naldini, 2002; De Palma et al., 2003).
Briefly, 106 cells/ml were transduced with a LV dose equivalent to 3–4 mg/ml
HIV p24 (for Tie2-IFN and PGK-IFN LVs) or 108 GFP-transducing units/ml
(for Tie2-GFP and PGK-GFP LVs) for 12 hr in serum-free StemSpan medium
(StemCell Technologies) containing a cocktail of cytokines (10 ng/ml IL-3,
20 ng/ml IL-6, 100 ng/ml SCF, and 10 ng/ml FL-3L, all from Serotec). After
transduction, 106 cells were infused into the tail vein of lethally irradiated
6-week-old female CD1 athymic or 5.5- or 8.5-week-old FVB/MMTV-PyMT
mice (radiation doses were 975 cGy for CD1 mice and 1100 cGy for FVB
mice). Transduced cells were also cultured in vitro for 5 days before FACS
analysis or for 9 days to measure IFN-a secretion by ELISA (R&D Systems).
Vector copy number in BM cells was measured by qPCR of vector sequences
at the end of the experiments as described previously (De Palma et al., 2005a).
Colony-forming cell assays were performed as described previously (De
Palma and Naldini, 2002; De Palma et al., 2003).
Statistical Analysis
In all studies, values are expressed as mean ± standard deviation (SD) or stan-
dard error of the mean (SEM), as indicated. Statistical analyses were per-
formed by unpaired Student’s t test unless indicated otherwise. Differences
were considered statistically significant at p < 0.05.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, and four figures and can be found with this article online
at http://www.cancercell.org/cgi/content/full/14/4/299/DC1/.
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